Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Rhea-AI Summary

On March 9, 2023, Alnylam Pharmaceuticals (Nasdaq: ALNY) and Medison Pharma announced an expansion of their partnership to include a multi-regional agreement covering Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia, Latvia, and Israel. This agreement aims to enhance the commercialization of Alnylam's RNA interference (RNAi) therapeutics, including ONPATTRO®, GIVLAARI®, and OXLUMO®. GIVLAARI® and OXLUMO® have already received reimbursement approval in Poland. The collaboration is expected to improve patient access to innovative therapies in Central and Eastern Europe, reflecting a commitment to addressing unmet medical needs in these regions.

Positive

• Expanded partnership with Medison Pharma enhances market reach.
• Approval of GIVLAARI® and OXLUMO® for reimbursement in Poland.
• Access to innovative therapies for patients in Central and Eastern Europe.

Negative

• None.

ZUG, Switzerland, March 9, 2023 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel. 

This new agreement builds upon the successful long-term partnership between Alnylam and Medison in Israel and will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNA interference (RNAi) therapeutics, such as ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO^® (lumasiran) are made available across additional countries in Europe. This expanded agreement is intended to ensure more efficient and effective commercialization. GIVLAARI® and OXLUMO® have already been approved for reimbursement in Poland, and Alnylam and Medison will work together to obtain additional reimbursements in the territories.

"We are delighted to extend our existing relationship with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in Central and Eastern Europe," said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam. "Medison is already one of our most significant partners, and their team has a wealth of experience to offer across our new markets. We look forward to continuing our collaboration and transforming more patients' lives together."

"The trust Alnylam shows in Medison's multi-regional commercial platform allows us to broaden patient access to Alnylam's highly innovative therapies across more countries," said Meir Jakobsohn, Founder and CEO of Medison. "Expanding our successful partnership will enable us to provide access to patients across Central and Eastern Europe who might otherwise not have access to these innovative treatment options."

"We are privileged to expand the access of Alnylam's groundbreaking treatments to additional markets. "Medison's multi regional platform makes us the partner of choice for emerging biotech companies seeking to make their innovative products available in international markets for the benefit of patients suffering from rare, debilitating disease", said Gil Gurfinkel, VP Corporate Development at Medison

About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), AMVUTTRA^® (vutrisiran) and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis.  Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P⁵x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. 

About Medison Pharma
Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets.

Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets. Medison has a track record of multi-territorial partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach.

To learn more visit www.medisonpharma.com

Contacts:

Alnylam Pharmaceuticals
Fiona McMillan, Head of Communications, International
T: +44 7741 655 570
E: fmcmillan@alnylam.com

Medison Pharma
Inbal Chen, Corporate Communications
T: +972-54-4400784
E: inbalc@medisonpharma.com

Logo - https://mma.prnewswire.com/media/1527224/MEDISON.jpg 
Logo - https://mma.prnewswire.com/media/2029506/Alnylam.jpg

 

View original content:https://www.prnewswire.com/news-releases/alnylam-pharmaceuticals-and-medison-pharma-announce-the-expansion-of-their-collaboration-to-a-multi-regional-partnership-to-commercialize-rnai-therapeutics-301767787.html

SOURCE Medison Pharma; Alnylam Pharmaceuticals

FAQ

What recent partnership did Alnylam Pharmaceuticals announce?

Alnylam Pharmaceuticals announced an expanded partnership with Medison Pharma to include a multi-regional agreement for commercialization in several European countries.

Which countries are included in Alnylam's new multi-regional agreement?

The agreement includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia, Latvia, and Israel.

What are the RNAi therapeutics involved in Alnylam's partnership with Medison?

The RNAi therapeutics involved include ONPATTRO®, GIVLAARI®, and OXLUMO®.

Have any of Alnylam's products been approved for reimbursement?

Yes, GIVLAARI® and OXLUMO® have been approved for reimbursement in Poland.